AR096617A1 - Anticuerpos anti-tweakr y sus usos - Google Patents
Anticuerpos anti-tweakr y sus usosInfo
- Publication number
- AR096617A1 AR096617A1 ARP140102273A ARP140102273A AR096617A1 AR 096617 A1 AR096617 A1 AR 096617A1 AR P140102273 A ARP140102273 A AR P140102273A AR P140102273 A ARP140102273 A AR P140102273A AR 096617 A1 AR096617 A1 AR 096617A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- acid sequence
- antibody
- amino acid
- formula
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 6
- 239000000427 antigen Substances 0.000 abstract 5
- 102000036639 antigens Human genes 0.000 abstract 5
- 108091007433 antigens Proteins 0.000 abstract 5
- 239000012634 fragment Substances 0.000 abstract 5
- 102000016946 TWEAK Receptor Human genes 0.000 abstract 2
- 108010014401 TWEAK Receptor Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical group 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 239000000611 antibody drug conjugate Substances 0.000 abstract 1
- 229940049595 antibody-drug conjugate Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Reivindicación 1: Un anticuerpo anti-TWEAKR aislado o uno de sus fragmentos de unión a antígeno, que específicamente se une con D en la posición 47 (D47) de TWEAKR tal como se representa en SEC ID Nº 169. Reivindicación 3: El anticuerpo o uno de sus fragmentos de unión a antígeno de acuerdo con las reivindicaciones 1 ó 2, que comprende: una cadena pesada variable que comprende: (a) una CDR1 de cadena pesada codificada por una secuencia de aminoácidos que comprende la fórmula PYPMX (SEC ID Nº 171), en la que X es I o M; (b) una CDR2 de cadena pesada codificada por una secuencia de aminoácidos que comprende la fórmula YISPSGGXTHYADSVKG (SEC ID Nº 172), en la que X es S o K; y (c) una CDR3 de cadena pesada codificada por una secuencia de aminoácidos que comprende la fórmula GGDTYFDYFDY (SEC ID Nº 173); y una cadena liviana variable que comprende: (a) una CDR1 de cadena liviana codificada por una secuencia de aminoácidos que comprende la fórmula RASQSISXYLN (SEC ID Nº 174), en la que X es G o S; (b) una CDR2 de cadena liviana codificada por una secuencia de aminoácidos que comprende la fórmula XASSLQS (SEC ID Nº 175), en la que X es Q, A o N; y (c) una CDR3 de cadena liviana codificada por una secuencia de aminoácidos que comprende la fórmula QQSYXXPXIT (SEC ID Nº 176), en la que X en la posición 5 es T o S y X en la posición 6 es T o S y X en la posición 8 es G o F. Reivindicación 12: Una secuencia de ácido nucleico aislada que codifica el anticuerpo o fragmento de unión a antígeno de acuerdo con las reivindicaciones 1 a 10. Reivindicación 14: Una célula aislada que expresa un anticuerpo o fragmento de unión a antígeno de acuerdo con cualquiera de las reivindicaciones 1 a 10 y/o que comprende un ácido nucleico de acuerdo con la reivindicación 12 o un vector de acuerdo con la reivindicación 13. Reivindicación 20: Una composición farmacéutica que comprende un anticuerpo o fragmento de unión a antígeno de acuerdo con las reivindicaciones 1 - 10 o un conjugado de anticuerpo-fármaco de acuerdo con la reivindicación11. Reivindicación 22: Un procedimiento para tratar un trastorno o afección asociados con la presencia indeseada de TWEAKR, que comprende la administración a un sujeto que lo necesita de una cantidad efectiva de la composición farmacéutica de acuerdo con la reivindicación 20 o una combinación de acuerdo con la reivindicación 21.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13172111 | 2013-06-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR096617A1 true AR096617A1 (es) | 2016-01-20 |
Family
ID=48607166
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140102273A AR096617A1 (es) | 2013-06-14 | 2014-06-13 | Anticuerpos anti-tweakr y sus usos |
ARP150101872A AR101544A1 (es) | 2013-06-14 | 2015-06-11 | Anticuerpos anti-tweakr aglicosilados y usos de los mismos |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP150101872A AR101544A1 (es) | 2013-06-14 | 2015-06-11 | Anticuerpos anti-tweakr aglicosilados y usos de los mismos |
Country Status (16)
Country | Link |
---|---|
US (1) | US20160237160A1 (es) |
EP (1) | EP3008090A1 (es) |
JP (1) | JP2016521715A (es) |
KR (1) | KR20160019434A (es) |
CN (1) | CN105308070A (es) |
AR (2) | AR096617A1 (es) |
AU (1) | AU2014280174A1 (es) |
BR (1) | BR112015029953A2 (es) |
CA (1) | CA2915311A1 (es) |
HK (1) | HK1216893A1 (es) |
MX (1) | MX2015016814A (es) |
PE (1) | PE20160716A1 (es) |
RU (1) | RU2016100892A (es) |
SG (1) | SG11201509116VA (es) |
TW (1) | TW201534623A (es) |
WO (1) | WO2014198817A1 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015189143A1 (en) * | 2014-06-12 | 2015-12-17 | Bayer Pharma Aktiengesellschaft | Aglycosyl anti-tweakr antibodies and uses thereof |
US10584175B2 (en) | 2014-10-23 | 2020-03-10 | La Trobe University | FN14-binding proteins and uses thereof |
CN105779576A (zh) * | 2014-12-25 | 2016-07-20 | 中国人民解放军第四军医大学 | 人tnfrsf12a基因的用途及其相关药物 |
JP6451497B2 (ja) * | 2015-05-20 | 2019-01-16 | 富士通株式会社 | 情報処理装置、情報処理プログラム、及びデータセンタシステム |
CN114917361A (zh) | 2015-06-22 | 2022-08-19 | 拜耳医药股份有限公司 | 具有酶可裂解基团的抗体药物缀合物(adc)和抗体前药缀合物(apdc) |
US20180318438A1 (en) | 2015-06-23 | 2018-11-08 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-tweakr-antibodies |
WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
KR20180123047A (ko) | 2016-03-24 | 2018-11-14 | 바이엘 파마 악티엔게젤샤프트 | 효소적으로 절단가능한 기를 갖는 세포독성 활성제의 전구약물 |
EP3919518A1 (en) | 2016-06-15 | 2021-12-08 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
AU2017308734A1 (en) * | 2016-08-12 | 2019-02-14 | Janssen Biotech, Inc. | Fc engineered anti-TNFR superfamily member antibodies having enhanced agonistic activity and methods of using them |
CN106244612B (zh) * | 2016-08-30 | 2018-02-06 | 厦门瑞百泰生物医药有限公司 | 一种在大肠杆菌中制备基因工程IgG抗体的方法 |
PE20191235A1 (es) | 2016-12-21 | 2019-09-11 | Bayer Pharma AG | Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente |
EP3558387B1 (de) | 2016-12-21 | 2021-10-20 | Bayer Pharma Aktiengesellschaft | Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren |
CN110312533B (zh) | 2016-12-21 | 2023-11-03 | 拜耳公司 | 具有酶促可裂解的基团的细胞毒性活性剂的前药 |
US10724038B1 (en) * | 2017-12-10 | 2020-07-28 | Persona Biomed, Inc. | Target-oriented therapeutic drug and in-vitro method of discovery thereof for modulating onset or progression of liver metastasis |
JP2021512103A (ja) | 2018-01-31 | 2021-05-13 | バイエル アクチェンゲゼルシャフトBayer Aktiengesellschaft | Nampt阻害剤を含む抗体薬物複合体(adcs) |
US20210340263A1 (en) * | 2018-08-09 | 2021-11-04 | The Wistar Institute | Anti-Follicule Stimulating Hormone Receptor Antibodies |
SG11202104463YA (en) * | 2018-10-31 | 2021-05-28 | Astellas Pharma Inc | Anti-human fn14 antibody |
WO2021013693A1 (en) | 2019-07-23 | 2021-01-28 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
CN114107305B (zh) * | 2021-12-14 | 2023-11-28 | 朱博 | 一种低温诱导型增强子及其在植物低温诱导时增强基因表达中的应用 |
CN115951055A (zh) * | 2022-12-13 | 2023-04-11 | 广州顺泰生物医药科技有限公司 | 一种癌症相关蛋白及其抗体和应用 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
WO1997008320A1 (en) | 1995-08-18 | 1997-03-06 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
DK1068241T3 (da) | 1998-04-02 | 2008-02-04 | Genentech Inc | Antistofvarianter og fragmenter deraf |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP1648936B1 (en) * | 2003-07-24 | 2007-06-06 | Amgen Inc. | Compositions and methods relating to multimeric and oligomeric soluble fragments of the tweak receptor |
WO2006130429A2 (en) * | 2005-05-27 | 2006-12-07 | Biogen Idec Ma Inc. | Treatment of cancer |
EP2545938A1 (en) | 2007-08-03 | 2013-01-16 | Abbott Biotherapeutics Corp. | Therapeutic use of anti-tweak receptor antibodies |
BRPI0912198A2 (pt) | 2008-05-15 | 2019-09-24 | Biogen Idec Inc | anticorpos anti-fn14 e usos dos mesmos |
EP2508525A1 (en) | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
CA2845946A1 (en) * | 2011-08-23 | 2013-02-28 | Transbio Ltd | Fn14-binding proteins and uses thereof |
-
2014
- 2014-06-12 TW TW103120286A patent/TW201534623A/zh unknown
- 2014-06-12 JP JP2016518488A patent/JP2016521715A/ja active Pending
- 2014-06-12 US US14/898,455 patent/US20160237160A1/en not_active Abandoned
- 2014-06-12 KR KR1020157035015A patent/KR20160019434A/ko not_active Application Discontinuation
- 2014-06-12 BR BR112015029953A patent/BR112015029953A2/pt not_active Application Discontinuation
- 2014-06-12 RU RU2016100892A patent/RU2016100892A/ru not_active Application Discontinuation
- 2014-06-12 WO PCT/EP2014/062207 patent/WO2014198817A1/en active Application Filing
- 2014-06-12 MX MX2015016814A patent/MX2015016814A/es unknown
- 2014-06-12 SG SG11201509116VA patent/SG11201509116VA/en unknown
- 2014-06-12 EP EP14734415.4A patent/EP3008090A1/en not_active Withdrawn
- 2014-06-12 AU AU2014280174A patent/AU2014280174A1/en not_active Abandoned
- 2014-06-12 PE PE2015002575A patent/PE20160716A1/es not_active Application Discontinuation
- 2014-06-12 CA CA2915311A patent/CA2915311A1/en not_active Abandoned
- 2014-06-12 CN CN201480033756.4A patent/CN105308070A/zh active Pending
- 2014-06-13 AR ARP140102273A patent/AR096617A1/es unknown
-
2015
- 2015-06-11 AR ARP150101872A patent/AR101544A1/es unknown
-
2016
- 2016-04-19 HK HK16104445.5A patent/HK1216893A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CN105308070A (zh) | 2016-02-03 |
KR20160019434A (ko) | 2016-02-19 |
US20160237160A1 (en) | 2016-08-18 |
SG11201509116VA (en) | 2015-12-30 |
AU2014280174A1 (en) | 2015-12-03 |
EP3008090A1 (en) | 2016-04-20 |
JP2016521715A (ja) | 2016-07-25 |
MX2015016814A (es) | 2016-08-08 |
WO2014198817A1 (en) | 2014-12-18 |
HK1216893A1 (zh) | 2016-12-09 |
TW201534623A (zh) | 2015-09-16 |
RU2016100892A (ru) | 2017-07-19 |
BR112015029953A2 (pt) | 2017-09-26 |
PE20160716A1 (es) | 2016-08-11 |
CA2915311A1 (en) | 2014-12-18 |
AR101544A1 (es) | 2016-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR096617A1 (es) | Anticuerpos anti-tweakr y sus usos | |
CL2019001926A1 (es) | Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017). | |
CY1124771T1 (el) | Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων | |
AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
AR102239A1 (es) | Anticuerpos anti-ox40 humanizados y sus usos | |
PE20191208A1 (es) | Anticuerpos anti-cd73 y usos de los mismos | |
ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
PH12017500297A1 (en) | Anti-lag3 antibodies and antigen-binding fragments | |
PE20221580A1 (es) | Anticuerpos terapeuticos y sus usos | |
PE20171654A1 (es) | Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer | |
PE20142243A1 (es) | Anticuerpos que se unen a ox40 y sus usos | |
PE20190970A1 (es) | Anticuerpos anti-cd40 y sus usos | |
PE20131209A1 (es) | Anticuerpos anti-fap | |
CO6430469A2 (es) | Anticuerpos humanizados que se unen a cd19 y sus usos | |
AR109715A1 (es) | Anticuerpos anti-cd27 | |
AR095980A1 (es) | Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización | |
PE20181054A1 (es) | Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion | |
UA115781C2 (uk) | Cx3cr1-зв'язуючий поліпептид | |
PE20121649A1 (es) | Anticuerpos monoclonales frente a progastrina y sus usos | |
AR109683A1 (es) | Anticuerpos contra el factor xi y sus usos | |
EA201790816A1 (ru) | Антитела, которые связываются с ccr6, и варианты применения указанных антител | |
AR096445A1 (es) | Anticuerpos que se unen específicamente a la subunidad b de la toxina shiga | |
AR108451A1 (es) | Anticuerpos anti-tenascina modificados y métodos de utilización |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |